Your session is about to expire
← Back to Search
Short-Course Radiation for Endometrial Cancer (DeCRESCEndo Trial)
DeCRESCEndo Trial Summary
This trial is testing whether a shorter course of radiation is just as effective as the standard radiation treatment for endometrial cancer patients.
DeCRESCEndo Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowDeCRESCEndo Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 trial • 68 Patients • NCT00057785DeCRESCEndo Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can take care of myself but might not be able to do heavy physical work.You are currently taking experimental drugs.I do not have any ongoing serious illnesses like heart failure or severe infections.I am 18 years old or older.I can understand and am willing to sign a consent form.I have had radiation treatment to my pelvic area.My cancer is confirmed to be a specific type of advanced endometrial cancer.I have HIV but my CD4+ T-cell count is above 350 and I haven't had any major infections in the last year.I had a radical hysterectomy within the last year.
- Group 1: IMRT
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the prime goals of this clinical experiment?
"The focal metric of this medical trial, occurring over a four week period from commencement to cessation of radiation therapy, is the incidence of late-term hematologic, gastrointestinal and genitourinary adverse events. Secondary outcomes include locoregional control (through histological or radiographic evidence), quality of life as measured by FACT-En questionnaire scores ranging from 0 - 4 with higher values indicating better health state and overall disease free survival."
What is the uppermost limit for participants in this experiment?
"Indeed, the clinicaltrials.gov database indicates that this trial is still actively recruiting patients. The study was initially advertised on July 7th 2020 and has since been amended for the last time on July 27th 2022. 25 participants are needed at one medical centre."
Is there availability to join this research endeavor?
"Indeed, the information accessible on clinicaltrials.gov suggests that this research is actively enrolling individuals. It was first listed on July 7th 2020 and has been recently updated in late July of 2022. 25 participants are sought after across one site location."
Share this study with friends
Copy Link
Messenger